<DOC>
	<DOCNO>NCT00001296</DOCNO>
	<brief_summary>Randomized study . Initially , 3 patient enter Arm I pilot feasibility study standardize technical aspect study . Subsequently , patient randomize Arms I II . Arm I : Regional Hyperthermia plus Regional Single-Agent Chemotherapy . Hyperthermic intravenous limb perfusion , HILP ; plus Melphalan , L-PAM , NSC-8806 . Arm II : Regional Hyperthermia plus Regional Single-Agent Chemotherapy Biological Response Modifier Therapy . HILP Arm I ; plus L-PAM ; Tumor Necrosis Factor ( Knoll ) , TNF , NSC-635257 ; Interferon gamma ( Genentech ) , IFN-G , NSC-600662 .</brief_summary>
	<brief_title>A Randomized Phase III Trial Hyperthermic Isolated Limb Perfusion With Melphalan , Tumor Necrosis Factor , Interferon-Gamma Patients With Locally Advanced Extremity Melanoma</brief_title>
	<detailed_description>Patients locally advance melanoma confine extremity ( Stage IIIA Stage IIIAB ) treat randomized Phase III study hyperthermic isolated limb perfusion . One arm study standard 60 minute perfusion melphalan single agent . The second arm study combine melphalan , tumor necrosis factor , interferon-gamma isolated limb perfusion reproduce regimen show 100 % response rate Phase II European trial . Patients follow local response rate , duration response , treatment toxicity , disease-free survival .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven Stage IIIA IIIAB melanoma ( M.D . Anderson stag system ) extremity , follow : Advanced local disease indicate 2 satellite intransit metastasis . Lower limb regional metastasis must distal apex femoral triangle except inguinal lymph node metastasis . Upper limb regional metastasis must distal deltoid insertion except axillary lymph node metastasis . No evidence systemic disease outside involve extremity . Recurrent disease subsequent prior successful limb perfusion allow . Bidimensional directly measurable dermal subcutaneous lesion require . PRIOR/CONCURRENT THERAPY : No prior isolate limb perfusion . Biologic Therapy : At least 1 month since Biologic Therapy . At least 3 month since regional therapy extremity . Chemotherapy : At least 1 month since chemotherap.y At least 3 month since regional therapy extremity . Endocrine Therapy : Not specify . Radiotherapy : At least 1 month since radiotherapy . Surgery : Not specify . PATIENT CHARACTERISTICS : Age : 18 . Performance status : ECOG 0 1 . Hematopoietic : Platelets great 150,000 . Hepatic : Bilirubin le 1.5 mg/dl ; Coagulation profile normal . Renal : Creatinine le 2.0 mg/dl . Cardiovascular : No evidence peripheral vascular disease , e.g . : No history claudication . OTHER : HIV negative . No pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Interferon-Gamma</keyword>
	<keyword>Isolated Limb Perfusion</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Melphalan</keyword>
	<keyword>TNF</keyword>
</DOC>